Targeted delivery of siRNA against P65 and Snai1 effectively inhibited the expression of P-p65 and Snai1 in renal tubules, leading to reduced tubulointerstitial inflammation and fibrosis, significantly ameliorating I/R- and UUO-induced renal injury and effectively blocking the progression of AKI to CKD [108]. This evidence concerns the gene SNAI1 and chronic kidney disease.